% | $
Quotes you view appear here for quick access.

Celgene Corporation Message Board

  • whogo70 whogo70 Dec 16, 2012 11:15 PM Flag

    ASCO in January. You better start adding now if you want shares.

    "Melanoma and pancreatic cancer indications put Abraxane on $1B trajectory. Our FY12 revenue estimate for Abraxane is currently $460M. We estimate the revenue potential from melanoma is in the $200-250M range while pancreatic cancer could add another $500M-1B depending on the magnitude of the clinical benefit. CELG presented positive data from a pivotal Phase 3 trial for Abraxane in melanoma cancer earlier this week at the Society for Melanoma Research annual meeting. In January 2013, CELG will present the results of their Phase 3 registration study for Abraxane in pancreatic cancer at the ASCO GI Symposium".

    Brean Murray, Carret & Co

    Brean Capital

    Initiation of Coverage

    November 21, 2012

2.04+0.01(+0.49%)Jul 31 3:33 PMEDT